Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | NEK2 | P51955 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13080474 | 0.81 | MPO (0.56) | MPOPOLBESR2PDE7AMAPK1 | |
| SCHEMBL27783210 | 0.80 | MPO (0.45) | MPOPOLBESR2ALDH1A1KDM4E | |
| SCHEMBL1921321 | 0.77 | MPO (0.50) | MPOESR2MAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL24827532 | 0.75 | POLB (0.52) | POLBMAPK1ALDH1A1KDM4EHPGD | |
| SCHEMBL1921784 | 0.75 | MPO (0.46) | MPOPOLBESR2ALDH1A1KDM4E | |
| SCHEMBL29028700 | 0.74 | MPO (0.47) | MPOESR2MAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL1921361 | 0.74 | MPO (0.47) | MPOPOLBESR2ALDH1A1KDM4E | |
| SCHEMBL29043091 | 0.74 | CNR2 (0.48) | MPO | |
| SCHEMBL1921110 | 0.74 | CNR2 (0.48) | MPO | |
| SCHEMBL1920947 | 0.73 | MPO (0.47) | MPOPOLBMAPK1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283476-B2 | Transition metal catalyzed synthesis of 2H-indazoles | SANOFI (FR) | 2012-10-09 | — | — | US | claimed |
| EP-2170833-B1 | A TRANSITION METAL CATALYZED SYNTHESIS OF 2H-INDAZOLES | SANOFI AVENTIS (FR) | 2011-06-01 | — | — | EP | claimed |
| US-20100234601-A1 | Transition metal catalyzed synthesis of 2H-indazoles | SANOFI-AVENTIS (FR) | 2010-09-16 | — | — | US | claimed |
| EP-2170833-A1 | A TRANSITION METAL CATALYZED SYNTHESIS OF 2H-INDAZOLES | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | claimed |
| WO-2009000411-A1 | A TRANSITION METAL CATALYZED SYNTHESIS OF 2H-INDAZOLES | SANOFI-AVENTIS (FR) | 2008-12-31 | — | — | WO | claimed |
| US-8283476-B2 | Transition metal catalyzed synthesis of 2H-indazoles | SANOFI (FR) | 2012-10-09 | — | — | US | disclosed |
| US-8283476-B2 | Transition metal catalyzed synthesis of 2H-indazoles | SANOFI (FR) | 2012-10-09 | — | — | US | disclosed |
| EP-2170833-B1 | A TRANSITION METAL CATALYZED SYNTHESIS OF 2H-INDAZOLES | SANOFI AVENTIS (FR) | 2011-06-01 | — | — | EP | disclosed |
| US-20100234601-A1 | Transition metal catalyzed synthesis of 2H-indazoles | SANOFI-AVENTIS (FR) | 2010-09-16 | — | — | US | disclosed |
| EP-2170833-A1 | A TRANSITION METAL CATALYZED SYNTHESIS OF 2H-INDAZOLES | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009000411-A1 | A TRANSITION METAL CATALYZED SYNTHESIS OF 2H-INDAZOLES | SANOFI-AVENTIS (FR) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234601-A1 | Transition metal catalyzed synthesis of 2H-indazoles | H1-3, H1-2, H1-4 | MPO 1473/4885POLB 2363/4885ESR2 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.